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REML - ﬁxed-effects - model, rose-hip resulted in a statistically
signiﬁcant small reduction in pain (ES [95% CI]: -0.21 [-0.35 to
-0.07]; p=0.004), disability (-0.22 [-0.36 to -0.07]; p=0.003), with
more patients likely to respond to treatment when compared to
the untreated controls (OR: 3.04 [2.04 to 4.52]; p<0.0001). This
OR - adjusted for the weighted control event rate - corresponded
to a NNT of 4 (3 to 6) patients.
Conclusions:Based on the available evidence, we conclude that
a supplement of rose-hip might result in some symptomatic relief
in many osteoarthritis patients. The clinical efﬁcacy was small
and in the same range as that of paracetamol (acetaminophen).
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Purpose: To compare the efﬁcacy of 1x6mL intra-articular (IA)
administration of hylan G-F 20 (Synvisc-One™) against placebo
in different sub-populations of patients with symptomatic OA of
the knee.
Methods: Prospective, multicenter, randomized, double-blind
(patient, independent clinical observer) study comparing 1 IA
injection of 6mL of hylan G-F 20 (H) or saline (S). Patients must
have documented diagnosis of OA of the target knee made at
least 3 months prior to screening. Patients with symptomatic OA
of the contralateral knee or either hip not responsive to parac-
etamol and requiring other therapy were excluded. The primary
efﬁcacy analysis used WOMAC A Likert pain and was performed
on the ITT population, based on a repeated-measures model
over the 26 weeks of the follow up.
Results: 253 patients were randomized (H N=124, S N=129).
Mean age 63 years (42-84), BMI 29.4 (19.5-52.4), 71% fe-
male, primary knee OA Kellgren Lawrence (KL) grade 2 (45%)
or 3 (55%). Overall, patients in the H group experienced a
mean change from baseline in their WOMAC A pain score over
26 weeks which was statistically signiﬁcantly different from the
change reported in the S group ( = -0.15, p = 0.047).
The OA status in the contralateral knee and hips made a differ-
ence with hylan G-F 20 being more effective over 26 weeks in
the patients without other joints involvement (N = 105,  = -0.31)
as compared to patients with symptomatic OA in lower limbs (N
= 148,  = -0.04, treatment by OA interaction p = 0.03).
Similarly, hylan G-F 20 tends to have a greater effect over 26
weeks in patients with KL grade 0-II tibio-femoral OA (N = 114,
 = -0.22) as compared with grade III-IV (N = 139  = -0.08,
interaction p = 0.17).
In the subgroup of patients with severe baseline WOMAC A1
pain, hylan G-F 20 demonstrated a greater symptomatic effect at
week 26 (N = 90,  = -0.28) than in the subgroup with moderate
baseline pain (N = 163,  = -0.13), but there was no statistical
difference over the 26 weeks of the study.
Conclusions: In this study, the positive predictive factors of
symptomatic response after IA injection of a single 6 ml dose of
hylan G-F 20 in patients with knee OA were high level of baseline
pain, early grade OA and no concurrent lower limb OA.
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Purpose: Osteoarthritis (OA) is among the most common causes
of disability in the elderly. Since the recent publications illustrat-
ing the lethal adverse affects of cox-2 selective anti-inﬂamatory
drugs, there has emerged a need for safe long term treatment in
OA. As a result, patients have begun using dietary supplements
sold OTC. These include glucoseamine, chondroitine sulfate and
methylsulfonylmethane (MSM). MSM is a natural substance pro-
duced in our body that has analgesic and anti-inﬂammatory
properties. There is lack of research on the efﬁcacy of MSM in
treating knee OA. The aim of the study was to determine the
efﬁcacy of MSM in treating knee OA patients.
Methods: This study is a prospective, randomized, double-
blinded, controlled study. 60 men and women, 45-90 (68 ±7.3)
years of age with knee OA graded 1-4 (3 ±1) according to
Kellgren & Lawrence, were enrolled in the study and randomly
assigned into 2 groups: One receiving MSM in doses of 1.125
milligrams 3 times daily, and the other receiving a placebo. Pa-
tients were assessed at baseline, 6, and 12 weeks. During their
appointments, the patients were asked to ﬁll out questioners
on their pain and physical function: SF-36, WOMAC, KFS, and
KSS. The patients physical function was also assessed using
Aggregated Locomotor Function (ALF).
Results: There were signiﬁcant improvements in pain, stiffness,
and physical function in the experimental group according to
both the WOMAC questioner (p-value=0.009) and the SF36
questioner (p-value=0.031). No signiﬁcant differences between
the groups were found using the KSS and KFS questioners. A
seven second improvement in the total time measured (ALF) was
also found in the study group, while no such improvement was
seen in the placebo group (p-value=0.009). No adverse effects
were recorded.
Conclusions: The ﬁndings demonstrate that methylsulfonyl-
methane (MSM) is effective and signiﬁcantly improve function
and reduce pain in knee OA patients.
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Purpose: Reports of cardiovascular adverse events associated
with the use of GI-COX-2 speciﬁc inhibitors for chronic therapy
of osteoarthritis have prompted the quest for a safer NSAID. The
present study was undertaken to compare the efﬁcacy, safety
and tolerability of oral lornoxicam and diclofenac in adult Indian
patients with osteoarthritis.
Methods: This prospective, double-blind, randomized, compar-
ative, multicentric study was undertaken in 260 adult Indian
patients, in 5 centers across the country. The study protocol
was approved by respective Institutional review boards. Written
informed consent was obtained from each patient prior to un-
